A comparative analysis of multidrug-resistant Escherichia coli in urinary tract infections among males and females (2022–2023)
Main Article Content
Keywords
urinary tract infection, UPEC, multidrug resistance, antibiotic sensitivity, antibiotic resistance
Abstract
Background: Uropathogenic Escherichia coli (UPEC) is a primary cause of urinary tract infections (UTIs) globally. The increasing antibiotic resistance of UPEC strains poses a significant challenge for treatment in countries like Iraq. Aim: The study aims to evaluate antimicrobial resistance patterns of Escherichia coli (E. coli) among UTI patients, considering age and sex, and to compare these findings with data from other geographical locations. Methods: Our study investigated antibiotic resistance patterns among E. coli strains responsible for UTIs in patients at Karbala Teaching Hospital for Children, Iraq. We specifically examined age and sex differences. Data on 144 E. coli isolates were collected and analyzed for their susceptibility to six antibiotics from January 1, 2022, to December 31, 2023. Results: There were no statistically significant sex-based differences in antibiotic resistance. Ceftriaxone (76%) and nalidixic acid (67%) demonstrated the highest resistance rates among the tested antibiotics in both sexes. In contrast, amikacin (91%) and gentamicin (60%) exhibited higher sensitivity rates compared to other antibiotics. A general trend of increasing antibiotic resistance with age was evident, particularly pronounced for nalidixic acid and ceftriaxone. Conclusion: Amikacin consistently demonstrated relatively low resistance rates across all age groups. Infants under one year of age displayed heightened susceptibility to certain antibiotics, as reflected in lower resistance rates. Conversely, nalidixic acid and ceftriaxone exhibited notably elevated resistance rates across all age groups.
References
2. Foxman B, Brown P. Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am. 2003;17(2):227–41.
3. Vasudevan R. Urinary tract infection: an overview of the infection and the associated risk factors. J Microbiol Exp. 2014;1(2):42–54.
4. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269–84.
5. Prakash D, Saxena RS. Prevalence and antimicrobial susceptibility pattern of Escherichia coli in hospital acquired and community acquired patients related to urinary tract infection in India. J Appl Pharm Sci. 2013;3(8):124–32.
6. Mann R, Mediati DG, Duggin IG, Harry EJ, Bottomley AL. Metabolic adaptations of uropathogenic E. coli in the urinary tract. Front Cell Infect Microbiol. 2017;7:241.
7. Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol. 2004 Feb;2(2):123–40.
8. Dehbanipour R, Rastaghi S, Sedighi M, Maleki N, Faghri J. High prevalence of multidrug-resistance uropathogenic Escherichia coli strains, Isfahan, Iran. J Nat Sci Biol Med. 2016;7(1):22–6.
9. Gunduz S, Altun HU. Antibiotic resistance patterns of urinary tract pathogens in Turkish children. Glob Health Res Policy. 2018;3:10.
10. Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas M, Giske C, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.
11. Mlugu EM, Mohamedi JA, Sangeda RZ, Mwambete KD. Prevalence of urinary tract infection and antimicrobial resistance patterns of uropathogens with biofilm forming capacity among outpatients in Morogoro, Tanzania: a cross-sectional study. BMC Infect Dis. 2023;23(1):660.
12. Cardiliya A, Chandrasekar M, Nanjan M. Incidence of biofilms among the multidrug resistant E. coli, isolated from urinary tract infections in the Nilgiris district, South India. Braz J Microbiol. 2023;54(3):1809–18.
13. McLellan LK, Hunstad DA. Urinary tract infection: pathogenesis and outlook. Trends Mol Med. 2016 Nov;22(11):946–57.
14. Assafi MS, Ali FF, Polis RF, Sabaly NJ, Qarani SM. An epidemiological and multidrug resistance study for E. coli isolated from urinary tract infection (three years of study). Baghdad Sci J. 2022;19(1):7–15.
15. Laswad EA. The rates incidence of urinary tract infection in the community and development uropathogens resistance to antibiotics. SJFSSU. 2023;3(2):96–104.
16. Grigoryan L, Trautner BW, Gupta K. Diagnosis and management of urinary tract infections in the outpatient setting: a review. JAMA. 2014;312(16):1677–84.
17. Momtaz H, Karimian A, Madani M, Dehkordi FS, Ranjbar R, Sarshar M, et al. Uropathogenic Escherichia coli in Iran: serogroup distributions, virulence factors and antimicrobial resistance properties. Ann Clin Microbiol Antimicrob. 2013 Apr 29;12:8.
18. Kibret M, Abera B. Prevalence and antibiogram of bacterial isolates from urinary tract infections at Dessie Health Research Laboratory, Ethiopia. Asian Pac J Trop Biomed. 2014;4(2):164–8.
19. Kolawole A, Kolawole O, Kandaki-Olukemi Y, Babatunde S, Durowade K, Kolawole C. Prevalence of urinary tract infections (UTI) among patients attending Dalhatu Araf Specialist Hospital, Lafia, Nasarawa state, Nigeria. IJMMS. 2009;1(5):163–7.
20. Ali I, Rafaque Z, Ahmed S, Malik S, Dasti JI. Prevalence of multi-drug resistant uropathogenic Escherichia coli in Potohar region of Pakistan. Asian Pac J Trop Biomed. 2016;6(1):60–6.
21. Conway PH, Cnaan A, Zaoutis T, Henry BV, Grundmeier RW, Keren R. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA. 2007;298(2):179–86.
22. Nguyen SN, Thi Le HT, Tran TD, Vu LT, Ho TH. Clinical epidemiology characteristics and antibiotic resistance associated with urinary tract infections caused by E. coli. Int J Nephrol. 2022;2022(1):2552990.
23. Huang L, Huang C, Yan Y, Sun L, Li H. Urinary tract infection etiological profiles and antibiotic resistance patterns varied among different age categories: a retrospective study from a tertiary general hospital during a 12-year period. Front Microbiol. 2022;12:813145.
24. Maxwell A, Ghate V, Aranjani J, Lewis S. Breaking the barriers for the delivery of amikacin: challenges, strategies, and opportunities. Life Sci. 2021;284:119883.
25. Kulkarni SR, Peerapur BV, Sailesh KS. Isolation and antibiotic susceptibility pattern of Escherichia coli from urinary tract infections in a tertiary care hospital of North Eastern Karnataka. J Nat Sci Biol Med. 2017;8(2):176–80.
26. Abduzaimovic A, Aljicevic M, Rebic V, Vranic SM, Abduzaimovic K, Sestic S. Antibiotic resistance in urinary isolates of Escherichia coli. Mater Sociomed. 2016;28(6):416–9.
27. Ali I, Shabbir M, Iman NU. Antibiotics susceptibility patterns of uropathogenic E. coli with special reference to fluoroquinolones in different age and gender groups. J Pak Med Assoc. 2017;67(8):1161–5.
28. Yasmeen BN, Islam S, Islam S, Uddin MM, Jahan R. Prevalence of urinary tract infection, its causative agents and antibiotic sensitivity pattern: a study in Northern International Medical College Hospital, Dhaka. Northern Int Med Coll J. 2015;7(1):105–9.
29. Thai T, Salisbury BH, Zito PM. Ciprofloxacin [Internet]. PubMed: Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://pubmed.ncbi.nlm.nih.gov/30571075/
30. Jadoon RJ, Khan SA. Jalal-ud-Din M. E. coli resistance to ciprofloxacin and common associated factors. J Coll Physicians Surg Pak. 2015;25(11):824–7.
31. Balakumar P, Rohilla A, Thangathirupathi A. Gentamicin-induced nephrotoxicity: do we have a promising therapeutic approach to blunt it? Pharmacol Res. 2010;62(3):179–86.
32. Hasegan A, Totan M, Antonescu E, Bumbu AG, Pantis C, Furau C, et al. Prevalence of urinary tract infections in children and changes in sensitivity to antibiotics of E. coli strains. Rev Chim. 2019;70:3788–92.
33. Ait-Mimoune N, Hassaine H, Boulanoir M. Bacteriological profile of urinary tract infections and antibiotic susceptibility of Escherichia coli in Algeria. Iran J Microbiol. 2022;14(2):156–60.
34. Hurst M, Lamb HM, Scott LJ, Figgitt DP. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs. 2002;62(14):2127–67.
35. Aggarwal N, Kumar R, Dureja P, Khurana J. Synthesis, antimicrobial evaluation and QSAR analysis of novel nalidixic acid based 1, 2, 4-triazole derivatives. Eur J Med Chem. 2011;46(9):4089–99.
36. Sharma S, Kaur N, Malhotra S, Madan P, Ahmad W, Hans C. Serotyping and antimicrobial susceptibility pattern of Escherichia coli isolates from urinary tract infections in pediatric population in a tertiary care hospital. J Pathog. 2016;2016(1):2548517.
37. Lamb HM, Ormrod D, Scott LJ, Figgitt DP. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs. 2002;62(7):1041–89.
38. Hossain A, Hossain SA, Fatema AN, Wahab A, Alam MM, Islam MN, et al. Age and gender-specific antibiotic resistance patterns among Bangladeshi patients with urinary tract infection caused by Escherichia coli. Heliyon. 2020 Jun 8;6(6):e04161
39. Fatima S, Muhammad IN, Usman S, Jamil S, Khan MN, Khan SI. Incidence of multidrug resistance and extended-spectrum beta-lactamase expression in community-acquired urinary tract infection among different age groups of patients. Indian J Pharmacol. 2018;50(2):69–74.
40. Lin W-H, Wang M-C, Liu P-Y, Chen P-S, Wen L-L, Teng C-H, et al. Escherichia coli urinary tract infections: host age-related differences in bacterial virulence factors and antimicrobial susceptibility. J Microbiol Immunol Infect. 2022;55(2):249–56.
41. Ormeño MA, Ormeño MJ, Quispe AM, Arias-Linares MA, Linares E, Loza F, et al. Recurrence of urinary tract infections due to Escherichia coli and its association with antimicrobial resistance. Microb Drug Resist. 2022;28(2):185–90.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.